


BKIDC-1553

Cat. No.:	HY-163438
CAS No.:	1951431-34-7
Molecular Formula:	C ₂₂ H ₂₃ N ₅ O ₂
Molecular Weight:	389.45
Target:	Angiotensin-converting Enzyme (ACE)
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research ^[1] .
In Vitro	BKIDC-1553 (1.25-20 μM, 72 h) inhibits cell proliferation dose-dependently in various human PCa cell lines ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	BKIDC-1553 (20 mg/kg, p.o., 3 times weekly for 4 weeks) decreases tumor growth after 5 weeks in LuCaP 35 human PCa patient-derived xenograft mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Uo T, et al. A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. bioRxiv [Preprint]. 2024 Feb 13:2023.07.01.547355.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA